Rational Pharmacotherapy in Cardiology

Advanced search

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction

Full Text:


Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention is therefore recommended in patients with atrial fibrillation and decreased renal function. Each direct oral anticoagulant has unique pharmacologic properties of which clinician should be aware to optimally manage patients. The doses of direct oral anticoagulants require adjustment for renal function. There is debate regarding which equation, the Chronic Kidney Disease Epidemiology (CKD-EPI) equation vs. the Cockcroft-Gault equation, should be used to estimate glomerular filtration rate in patients with atrial fibrillation treated with direct oral anticoagulants. Our review tries to find arguments for benefit of direct oral anticoagulants in patients with renal dysfunction.

About the Authors

Z. D. Kobalava
Peoples Friendship University of Russia (RUDN University)
Russian Federation

Zhanna D. Kobalava


eLibrary SPIN 9828-5409

A. A. Shavarov
Peoples Friendship University of Russia (RUDN University)
Russian Federation

Andrey A. Shavarov


eLibrary SPIN 2506-1546

M. V. Vatsik-Gorodetskaya
V.V. Vinogradov City Clinical Hospital
Russian Federation

Maria V. Vatsik-Gorodetskaya



1. Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. DOI:10.1161/CIRCULATIONAHA.113.005119.

2. Eckardt K.U., Coresh J., Devuyst O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158-69. DOI:10.1016/S0140-6736(13)60439-0.

3. Boriani G., Savelieva I., Dan G.A., et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making - a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17:1169-96. DOI:10.1093/europace/euv202.

4. Friberg L., Hammar N., Ringh M., et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm cohort-study on atrial fibrillation (SCAF-study). Eur Heart J. 2006;27(16):1954-64. DOI:10.1093/eurheartj/ehl146.

5. Christiansen C.F., Schmidt M., Lamberg A.L., et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12:1449-54. DOI:10.1111/jth.12652.

6. Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011;25:271-8. DOI:10.1016/j.blre.2011.07.001.

7. Jun M., James M.T., Manns B.J., et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246. DOI:10.1136/bmj.h246.

8. Luo J.C., Leu H.B., Hou M.C., et al. Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med. 2013;126:e25-e32. DOI:10.1016/j.amjmed.2012.09.010.

9. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/eurheartj/ehw210.

10. Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83:2096-106. DOI:10.1111/bcp.13299.

11. Desai N.R., Krumme A.A., Schneeweiss S., et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation - quality and cost implications. Am J Med. 2014;127:1075-82. DOI:10.1016/j.amjmed.2014.05.013.

12. Watanabe H., Watanabe T., Sasaki S., et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158:629-36. DOI:10.1016/j.ahj.2009.06.031.

13. Conen D., Chae C.U., Glynn R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080-7. DOI:10.1001/jama.2011.659.

14. Shih C.J., Ou S.M., Chao P.W., et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation. 2016;133:265-72. DOI:10.1161/CIRCULATIONAHA.115.018294.

15. Bansal N., Fan D., Hsu C.Y., et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc. 2014;3:e001303. DOI:10.1161/JAHA.114.001303.

16. Friberg L., Benson L., Lip G.Y. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36:297-306. DOI:10.1093/eurheartj/ehu139.

17. Winkelmayer W.C., Patrick A.R., Liu J., et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22:349-57. DOI:10.1681/ASN.2010050459.

18. Goldstein B.A., Arce C.M., Hlatky M.A., et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation. 2012;126:2293-301. DOI:10.1161/CIRCULATIONAHA.112.099606.

19. Chao T.F., Liu C.J., Wang K.L., et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm. 2014;11:1752-9. DOI:10.1016/j.hrthm.2014.06.021.

20. Chan P.H., Huang D., Yip P.S., et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace. 2016;18:665-71. DOI:10.1093/europace/euv289.

21. Piccini J.P., Stevens S.R., Chang Y., et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224-32. DOI:10.1161/CIRCULATIONAHA.112.107128.

22. Roldan V., Marin F., Manzano-Fernandez S., et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109:956-60. DOI:10.1160/TH13-01-0054.

23. Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250. DOI:10.1161/JAHA.113.000250.

24. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:2246-76. DOI:10.1161/CIR.0000000000000665.

25. Bonde A.N., Lip G.Y., Kamper A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471-82. DOI:10.1016/j.jacc.2014.09.051.

26. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Aug 29:ehaa612. DOI:10.1093/eurheartj/ehaa612.

27. Ha J.T., Badve S.V., Jun M. Recent evidence for direct oral anticoagulants in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019;28(3):251-61. DOI:10.1097/MNH.0000000000000493.

28. Yang J.Y., Lee T.C., Montez-Rath M.E., et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol. 2012;23:495-506. DOI:10.1681/ASN.2011070658.

29. Hagendorn R., Farkas N., Vincze A., et al. Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: A meta-analysis. World J Gastroenterol. 2017;23:8415-25. DOI:10.3748/wjg.v23.i47.8415.

30. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NEJMoa1107039.

31. Abraham N.S., Noseworthy P.A., Yao X., et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014-22. DOI:10.1053/j.gastro.2016.12.018.

32. Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1-12. DOI:10.1007/s13318-018-0501-y.

33. Chang M., Yu Z., Shenker A., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637-45. DOI:10.1002/jcph.633.

34. Leil T.A., Frost C., Wang X., et al. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst Pharmacol. 2014;3:e136. DOI:10.1038/psp.2014.34.

35. Byon W., Sweeney K., Frost C., Boyd R. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):340-9. DOI:10.1002/psp4.12184.

36. Cirincione B., Kowalski K., Nielsen J., et al. Population pharmacokinetics of apixaban in subjects with non-valvular atrial fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728-38. DOI:10.1002/psp4.12347.

37. Wang X., Tirucherai G., Marbury T.C., et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628-36. DOI:10.1002/jcph.628.

38. Zeitouni M., Giczewska A., Lopes R.D., et al. Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020;75:1145-55. DOI:10.1016/j.jacc.2019.12.060.

39. Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1-16. DOI:10.1007/s40262-013-0100-7

40. Kubitza D., Becka M., Mueck W., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12. DOI:10.1111/j.1365-2125.2010.03753.x.

41. Mueck W., Lensing A, Agnelli G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86. DOI:10.2165/11595320-000000000-00000.

42. Blech S., Ebner T., Ludwig-Schwellinger E., et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99. DOI:10.1124/dmd.107.019083.

43. Stangier J., Rathgen K., Stahle H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303. DOI:10.1111/j.1365-2125.2007.02899.x.

44. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamicsof oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-68. DOI:10.2165/11318170-000000000-00000.

45. Delanaye P., Guerber F., Scheen A., et al. Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) equations: implications for refining drug dosage adjustment strategies. Clin Pharmacokinet. 2017;56(2):193-205. DOI:10.1007/s40262-016-0434-z.

46. Earley A., Miskulin D., Lamb E.J., et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization. A systematic review. Ann Intern Med. 2012;156:785-95. DOI:10.7326/0003-4819-156-6-201203200-00391.

47. Levey A.S., Greene T., Schluchter M.D., et al. Glomerular filtration rate measurement in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993;4:1159-71.

48. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12. DOI:10.7326/0003-4819-150-9-200905050-00006.

49. Delanaye P., Mariat C. The applicability of eGFR equations to different populations. Nat Rev Nephrol. 2013;9:513-22. DOI:10.1038/nrneph.2013.143.

50. Delanaye P., Cavalier E., Mariat C., et al. MDRD or CKD EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol. 2010;11:8. DOI:10.1186/1471-2369-11-8. DOI:10.1186/1471-2369-11-8.

51. Gaspari F., Ruggenenti P., Porrini E., et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 2013;84:164-73. DOI:10.1038/ki.2013.47.

52. MacIsaac R.J., Ekinci E.I., Premaratne E., et al. The chronic kidney Disease-Epidemiology collaboration (CKD-EPI) equation does not improve the underestimation of glomerular filtration rate (GFR) in people with diabetes and preserved renal function. BMC Nephrol. 2015;16:198. DOI:10.1186/s12882-015-0196-0.

53. Lingli X., Qing Z., Wenfang X. Diagnostic value of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations in diabetic patients: a systematic review and meta-analysis. J Int Med Res. 2020;48(6):1-15. DOI:10.1177/0300060520925950.

54. Matzke G.R., Aronoff G.R., Atkinson A.J., et al. Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122-37. DOI:10.1038/ki.2011.322.

55. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150. DOI:10.1038/kisup.2012.76

56. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. DOI:10.1159/000180580.

57. Millar J.A. The Cockroft and Gault formula for estimation of creatinine clearance: a friendly deconstruction. N Z Med J. 2012;125:119-22.

58. Flamant M., Haymann J.P., Vidal-Petiot E., et al. GFR estimation using the Cockcroft-Gault, MDRD Study, and CKD-EPI equations in the elderly. Am J Kidney Dis. 2012;60:847-9. DOI:10.1053/j.ajkd.2012.08.001.

59. Maccallum P.K., Mathur R., Hull S., et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3:e003343. DOI:10.1136/bmjopen-2013-003343.

60. Hellden A., Odar-Cederlof I., Nilsson G., et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;3:e002686. DOI:10.1136/bmjopen-2013-002686.

61. Melloni C., Peterson E.D., Chen A.Y., et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991-6. DOI:10.1016/j.jacc.2007.11.045.

62. Dufour B., Toussaint-Hacquard M., Kearney-Schwartz A. Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin. J Nutr Health Aging. 2012;16:647-52. DOI:10.1007/s12603-012-0072-6.

63. European Medicines Agency. Annex I. Summary of product characteristics: Pradaxa [cited Apr 5, 2020]. Available from:

64. European Medicines Agency. Annex I. Summary of product characteristics: Xarelto [cited Apr 5, 2020]. Available from:

65. European Medicines Agency. Annex I. Summary of product characteristics: Eliquis [cited Apr 5, 2020]. Available from:

66. Andrade J.G., Hawkins N.M., Fordyce C.B., et al. Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae. Can J Cardiol. 2018;34(8):1010-8. DOI:10.1016/j.cjca.2018.04.019.

67. Steinberg B.A., Holmes D.N., Piccini J.P., et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2:e000535. DOI:10.1161/JAHA.113.000535.

68. Camm A.J., Amarenco P., Haas S., et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145-53. DOI:10.1093/eurheartj/ehv466.

69. Yao X., Shah N.D., Sangaralingham L.R., et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779-90. DOI:10.21037/atm.2017.09.19.

70. Steinberg BA, Shrader P, Thomas L., et al. Off-label dosing of non- vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597-604. DOI:10.1016/j.jacc.2016.09.966.

71. Bell A.D., Gross P., Heffernan M., et al. Appropriate use of antithrombotic medication in Canadian patients with nonvalvular atrial fibrillation. Am J Cardiol. 2016;117:1107-11. DOI:10.1016/j.amjcard.2015.12.055.

72. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-94. DOI:10.1093/eurheartj/ehr342.

73. Andreu-Cayuelas J.M., Pastor-Perez F.J., Puche C.M., et al. Impact of variations in kidney function on nonvitamin K oral anticoagulant dosing in patients with atrial fibrillation and recent acute heart failure. Rev Esp Cardiol (Engl Ed). 2016;69:134-40. DOI:10.1016/j.rec.2015.06.021.

74. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-35. DOI:10.1056/NEJMoa1105594.

75. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.

76. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.

77. Sherwood M.W., Nessel C.C., Hellkamp A.S., et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66:2271- 2281. DOI:10.1016/j.jacc.2015.09.024.

78. Marijon E., Heuzey J.Y.L., Stuart Connolly S., et al. Causes of death and influencing factors in patients with atrial fibrillation. A competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128:2192-201. DOI:10.1161/CIRCULATIONAHA.112.000491.

79. Hijazi Z., Hohnloser S., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-70. DOI:10.1161/CIRCULATIONAHA.113.003628.

80. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-30. DOI:10.1093/eurheartj/ehs274.

81. Eikelboom J., MD, Geno Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Emerg Med. 2016;34(11S):3-8. DOI:10.1016/j.ajem.2016.09.046.

82. Schlieper G., Schwenger V., Remppis A., et al. [Anticoagulation in patients with chronic kidney disease: recommendations from the working group “Heart-Kidney” of the German Cardiac Society and the German Society of Nephrology] Internist (Berl). 2017;58:512-21. DOI:10.1007/s00108-017-0220-5.

83. Coresh J., Turin T.C., Matsushita K., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518-31. DOI:10.1001/jama.2014.6634.

84. Naimark D.M., Grams M.E., Matsushita K., et al. Past decline versus current eGFR and subsequent mortality risk. J Am Soc Nephrol. 2016;27:2456-66. DOI:10.1681/ASN.2015060688.

85. Chan K.E., Giugliano R.P., Patel M.R., et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888-99. DOI:10.1016/j.jacc.2016.02.082.

86. Kooiman J., van der Hulle T., Maas H., et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol. 2016;67:2442-4. DOI:10.1016/j.jacc.2016.03.516.

87. Dias C., Moore K.T., Murphy J., et al. Pharmacokinetics, pharmacodynamics, and safety of singledose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43:229-36. DOI:10.1159/000445328.

88. De Vriese A.S., Caluwe R., Bailleul E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015;66:91-8. DOI:10.1053/j.ajkd.2015.01.022.

89. Steffel J., Verhamme P., Potpara T., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;00:1-64. DOI:10.1093/eurheartj/ehy136.

90. Zhu J., Alexander G.C., Nazarian S., Segal J.B. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation. 2010-2017. Pharmacotherapy. 2018;38:907-20. DOI:10.1002/phar.2158.

For citation:

Kobalava Z.D., Shavarov A.A., Vatsik-Gorodetskaya M.V. Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction. Rational Pharmacotherapy in Cardiology. 2021;17(1):62-72. (In Russ.)

Views: 126

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)